Resetting the autoreactive immune system with a therapeutic peptide in lupus

Lupus

Volumn 24, Issue 4-5, 2015, Pages 412-418

  Schall, N ^a   Muller, S ^a  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Autophagy; HSPA8 HSC70; Lupus; Lupuzor; Peptide P140

Indexed keywords

CD4 ANTIGEN; FORIGERIMOD; HEAT SHOCK COGNATE PROTEIN 70; PLACEBO; IMMUNOLOGIC FACTOR; PEPTIDE FRAGMENT; SPLICEOSOMAL PEPTIDE P140;

ARTICLE; AUTOIMMUNITY; AUTOPHAGY; CD4+ T LYMPHOCYTE; DRUG MECHANISM; DRUG TOLERABILITY; FOLLOW UP; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNOMODULATION; LUPUS VULGARIS; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEDAI; TREATMENT OUTCOME; ANIMAL; DISEASE MODEL; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOUSE;

ANIMALS; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; PEPTIDE FRAGMENTS;

EID: 84925617945     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314556138     Document Type: Article

References (38)

1. Larché M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nature Med 2005; 11: S69-S75.
2. Zompra AA, Galanis AS, Werbitzky O, Albericio F. Manufacturing peptides as active pharmaceutical ingredients. Future Med Chem 2009; 1: 361-377.
3. Briand JP, Muller S. Emerging peptide therapeutics for inflammatory autoimmune diseases. Curr Pharm Des 2010; 16: 1136-1142.
4. Gentilucci L, De Marco R, Cerisoli L. Chemical modifications designed to improve peptide stability: Incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr Pharm Des 2010; 16: 3185-3203.
5. Albericio F, Kruger H. Therapeutic peptides. Future Med Chem 2012; 4: 1527-1531.
6. Patel A, Cholkar K, Mitra AK. Recent developments in protein and peptide parenteral delivery approaches. Ther Deliv 2014; 5: 335-365.
7. Wu AW, Stenzel MH. Drug carriers for the delivery of therapeutic peptides. Biomacromolecules 2014; 15: 1097-1114.
8. Paz Z, Tsokos GC. New therapeutics in systemic lupus erythematosus. Curr Opin Rheumatol 2013; 25: 297-303.
9. Wahren-Herlenius M, Dörner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013; 382: 819-831.
10. Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet 2014 22; 384 (9957): 1878-1888.
11. Monneaux F, Lozano JM, Patarroyo ME, Briand JP, Muller S. T cell recognition therapeutic effects of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MRL/lpr lupus mice. Eur J Immunol 2003; 33: 287-296.
12. Dieker J, Cisterna B, Monneaux F, et al. Apoptosis changes the phosphorylation status and subcellular localization of the spliceosomal autoantigen U1-70K. Cell Death Diff 2008; 15: 793-804.
13. Monneaux F, Briand J-P, Muller S. B and T cell immune response to snRNP in lupus mice Autoreactive CD4+ T cells recognize a T cell epitope located within the conserved RNP consensus sequence of the 70K protein. Eur J Immunol 2000; 20: 2191-2200.
14. Kattah NH, Kattah MG, Utz PJ. The U1-snRNP complex: Structural properties relating to autoimmune pathogenesis in rheumatic diseases. Immunol Rev 2010; 233: 126-145.
15. Monneaux F, Dumortier H, Steiner G, Briand J-P, Muller S. Murine models of systemic lupus erythematosus: B and T cell responses to spliceosomal ribonucleoproteins in MRL/Faslpr and (NZBxNZW)F1 lupus mice. Intern Immunol 2001; 13: 1155-1163.
16. Page N, Schall N, Strub J-M, et al. The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by γδ T cells. PloS ONE 2009; 4: e5273.
17. Lamanna G, Grillaud M, Macri C, Chaloin O, Muller S, Bianco A. Adamantane-based dendrons for trimerization of the therapeutic P140 peptide. Biomaterials 2014; 35: 7553-7561.
18. Schall N, Page N, Macri M, Chaloin O, Briand J-P, Muller S. Peptide-based approaches to treat lupus and other autoimmune diseases. J Autoimmunity 2012; 39: 143-153.
19. Radic M, Muller S. Epigenetics of autoantigens: New opportunities for therapy of autoimmune diseases. Genet Epigenet 2013; 5: 63-70.
20. Monneaux F, Hoebeke J, Sordet C, et al. Selective modulation of CD4+ T cells from lupus patients by a promiscuous, protective peptide analogue. J Immunol 2005; 175: 5839-5847.
21. Page N, Gros F, Schall N, et al. HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus. Ann Rheum Dis 2011; 70: 837-843.
22. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37: 269-390.
23. Alexander JJ, Quigg RJ. Systemic lupus erythematosus and the brain: What mice are telling us? Neurochem Int 2007; 50: 5-11.
24. Stricher F, Macri C, Ruff M, Muller S. HSPA8/HSC70 chaperone protein: Structure, function and chemical targeting. Autophagy 2013; 9: 1937-1954.
25. Paludan C, Schmid D, Landthaler M, et al. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 2005; 307: 593-596.
26. Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol 2013; 31: 443-473.
27. Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. Nat Rev Immunol 2013; 13: 722-737.
28. Monneaux F, Parietti V, Briand JP, Muller S. Intramolecular T cell spreading in unprimed MRL/lpr mice: Importance of the U1-70K protein sequence 131-151. Arthritis Rheum 2004; 50: 3232-3238.
29. Monneaux F, Parietti V, Briand J-P, Muller S. Importance of spliceosomal RNP1 motif for intermolecular T-B cell spreading and tolerance restoration in lupus. Arthritis Res Ther 2007; 9: R111.
30. Muller S, Wallace DJ. The importance of implementing proper selection of excipients in lupus clinical trials. Lupus 2014; 23: 609-614.
31. Gros F, Arnold J, Page N, et al. Macroautophagy is deregulated in murine and human lupus T lymphocytes. Autophagy 2012; 8: 1113-1123.
32. Pierdominici M, Vomero M, Barbati C, et al. Role of autophagy in immunity and autoimmunity, with a special focus on systemic lupus erythematosus. FASEB J 2012; 26: 1400-1412.
33. Clarke AJ, Ellinghaus U, Cortini A, et al. Autophagy is activated in systemic lupus erythematosus and required for plasmablast development. Ann Rheum Dis 2014. doi: 10.1136/annrheumdis- 2013-204343. [Epub ahead of print].
34. Gros F, Muller S. Pharmacological regulators of autophagy and their link with modulators of lupus disease. Br J Pharmacol 2014; 171: 4337-4359.
35. Massey AJ, Williamson DS, Browne H, et al. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother Pharmacol 2010; 66: 535-545.
36. Muller S, Monneaux F, Schall N, et al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus. Results of an early phase II clinical trial. Arthritis Rheum 2008; 58: 3873-3883.
37. Zimmer R, Wallace DJ, Muller S. Randomized, double-blind, placebo- controlled studies of P140 peptide in mannitol (Lupuzor) and trehalose (Forigerimod) in patients with SLE. Arthritis Rheum 2012; 64(Suppl. 10): 2620.
38. Zimmer R, Scherbarth HR, Rillo OL, Gomez-Reino J, Muller S. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis 2013; 72: 1830-1835.